MELANI RIBEIRO CUSTODIO

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/16 - Laboratório de Fisiopatologia Renal, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 7 de 7
  • article 2 Citação(ões) na Scopus
    Low Levels of Klotho are Associated with Intracranial Vascular Calcification in Patients with CKD
    (2021) CARVALHO, Luci Carla D. B.; VELOZO, Mariana P.; COELHO, Venceslau A.; CUSTODIO, Melani R.; DALBONI, Maria Aparecida; MOYSES, Rosa M. A.; ELIAS, Rosilene M.
  • article 1 Citação(ões) na Scopus
    Mineral and bone disorder after kidney transplantation (KTx)
    (2021) NEVES, C. L.; MARQUES, I. D. B.; CUSTóDIO, M. R.
    [No abstract available]
  • article 7 Citação(ões) na Scopus
    Aluminum Intoxication in Chronic Kidney Disease
    (2021) OLIVEIRA, R. B.; BARRETO, F. C.; NUNES, L. A.; CUSTóDIO, M. R.
  • article 6 Citação(ões) na Scopus
    Cardiovascular mortality in peritoneal dialysis: the impact of mineral disorders
    (2021) TRUYTS, César; CUSTODIO, Melani; PECOIT-FILHO, Roberto; MORAES, Thyago Proenca de; JORGETTI, Vanda
    Abstract Introduction: Mineral and bone disorders (MBD) are associated with higher mortality in dialysis patients. The main guidelines related to the subject, Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO), were elaborated based on published information from hemodialysis participants. The aim of our study was to evaluate the impact of calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) (according to guideline ranges from KDOQI and KDIGO) on the cardiovascular mortality of peritoneal dialysis (PD) patients. Methods: We used the BRAZPDII database, an observational multi-centric prospective study, which assessed participants on PD between December 2004 and January 2011. Amongst 9,905 participants included in this database, we analyzed 4424 participants who were on PD for at least 6 months. The appropriate confounding variables were entered into the model. Serum levels of Ca, P, and PTH were the variables of interest for the purposes of the current study. Results: We found a significant association between high P serum levels, categorized by KDOQI and KDIGO (P above 5.5 mg/dL), and cardiovascular survival (p < 0.01). Likewise, a compelling association was found between lower levels of PTH, categorized by guidelines (KDOQI and KDIGO - PTH less than 150 pg/mL, p < 0.01), and cardiovascular survival. Conclusion: In conclusion, levels of P above and PTH below the values proposed by KDOQI and KDIGO were associated with cardiovascular mortality in PD patients.
  • article 3 Citação(ões) na Scopus
    Treatment of Hyperparathyroidism (SHPT)
    (2021) HERNANDES, F. R.; GOLDENSTEIN, P.; CUSTóDIO, M. R.
  • article 0 Citação(ões) na Scopus
  • article 1 Citação(ões) na Scopus
    Parathyroid hormone levels after parathyroidectomy for secondary hyperparathyroidism
    (2021) NASCIMENTO JR., Climerio Pereira; ARAP, Sergio Samir; CUSTODIO, Melani Ribeiro; MASSONI NETO, Ledo Mazzei; BRESCIA, Marilia D'Elboux Guimaraes; MOYSES, Rosa Maria Affonso; JORGETTI, Vanda; MONTENEGRO, Fabio Luiz de Menezes
    OBJECTIVE: The parathormone level after parathyroidectomy in dialysis patients are of interest. Low levels may require cryopreserved tissue implantation; however, the resection is necessary in case of recurrence. We analyzed post parathyroidectomy parathormone levels in renal hyperparathyroidism. METHODS: Prospective observation of postoperative parathormone levels over defined periods in a cohort of dialysis patients that underwent total parathyroidectomy and immediate forearm autograft from 2008 to 2010, at a single tertiary care hospital. RESULTS: Of 33 patients, parathormone levels until 36 months could be divided into four patterns. Patients with stable function (Pattern 1) show relatively constant levels after two months (67% of the cases). Early function and later failure (Pattern 2) were an initial function with marked parathormone reduction before one year (18%). Graft recurrence (Pattern 3) showed a progressive increase of parathormone in four cases (12%). Complete graft failure (Pattern 4) was a nonfunctioning implant at any period, which was observed in one patient (3%). Parathormone levels of Pattern 3 became statistically different of Pattern 1 at 36 months. CONCLUSIONS: Patients that underwent the total parathyroidectomy and autograft present four different graft function patterns with a possible varied therapeutic management.